The development of therapeutic vaccines for cancer has met repeated disappointment over the years, as treatments aimed at cancers of the brain, lung and kidney have failed in clinical testing.
But now, developers like Moderna, BioNTech and Gritstone Bio are pushing forward with personalized, messenger RNA vaccines that have revitalized hopes these treatments could boost human immunity to keep cancer at bay.
